Amgen To Present At The 7th Annual Leerink Partners Global Healthcare Conference Read more about Amgen To Present At The 7th Annual Leerink Partners Global Healthcare Conference
Amgen CEO Robert A. Bradway Becomes PhRMA Board Chairman Read more about Amgen CEO Robert A. Bradway Becomes PhRMA Board Chairman
Amgen Reports Fourth Quarter And Full Year 2017 Financial Results Read more about Amgen Reports Fourth Quarter And Full Year 2017 Financial Results
Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label Read more about Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS® (carfilzomib) Label
Amgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results Read more about Amgen Announces Webcast of 2017 Fourth Quarter and Full Year Financial Results
Amgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments Read more about Amgen Reports Aimovig™ (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments
European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer Read more about European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label Read more about FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label
Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology Read more about Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab) Read more about European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)
